PRESENTATION

Q1 2022 — Presentation

Q1 2022PDF · 25 pages670 KB
DANAHER CORPORATION
First Quarter 2022 Earnings Release
April 21, 2022

-- 1 of 25 --

2
Forward Looking Statements
Statements in this presentation that are not strictly historical, including any statements regarding Danaher’s anticipated future financial performance and any other statements regarding events or
developments that we anticipate will or may occur in the future are "forward-looking" statements within the meaning of the federal securities laws. There are a number of important factors that could
cause actual results, developments and business decisions to differ materially from those suggested or indicated by such forward-looking statements and you should not place undue reliance on any
such forward-looking statements. These factors include, among other things, the highly uncertain and unpredictable severity, magnitude and duration of the COVID-19 pandemic (and the related
governmental, business and community responses thereto) on our business, results of operations and financial condition, the impact of our debt obligations on our operations and liquidity,
deterioration of or instability in the economy, the markets we serve and the financial markets (including as a result of the COVID-19 pandemic), uncertainties relating to U.S. laws or policies, including
potential changes in U.S. trade policies and tariffs and the reaction of other countries thereto, contractions or growth rates and cyclicality of markets we serve, competition, our ability to develop and
successfully market new products and technologies and expand into new markets, the potential for improper conduct by our employees, agents or business partners, our compliance with applicable
laws and regulations (including rules relating to off-label marketing and other regulations relating to medical devices and the health care industry), the results of our clinical trials and perceptions
thereof, our ability to effectively address cost reductions and other changes in the health care industry, our ability to successfully identify and consummate appropriate acquisitions and strategic
investments and successfully complete divestitures and other dispositions, our ability to integrate the businesses we acquire and achieve the anticipated growth, synergies and other benefits of such
acquisitions, contingent liabilities and other risks relating to acquisitions, investments, strategic relationships and divestitures (including tax-related and other contingent liabilities relating to past and
future IPOs, split-offs or spin-offs), security breaches or other disruptions of our information technology systems or violations of data privacy laws, the impact of our restructuring activities on our
ability to grow, risks relating to potential impairment of goodwill and other intangible assets, currency exchange rates, tax audits and changes in our tax rate and income tax liabilities, changes in tax
laws applicable to multinational companies, litigation and other contingent liabilities including intellectual property and environmental, health and safety matters, the rights of the United States
government to use, disclose and license certain intellectual property we license if we fail to commercialize it, risks relating to product, service or software defects, product liability and recalls, risks
relating to product manufacturing, our relationships with and the performance of our channel partners, uncertainties relating to collaboration arrangements with third-parties, commodity costs and
surcharges, our ability to adjust purchases and manufacturing capacity to reflect market conditions, reliance on sole sources of supply, the impact of deregulation on demand for our products and
services, the impact of climate change, or legal or regulatory measures to address climate change, labor matters and our ability to recruit, retain and motivate talented employees, international
economic, political, legal, compliance, social and business factors (including the impact of the United Kingdom's separation from the European Union and the impact of the military conflict between
Russia and Ukraine), disruptions relating to man-made and natural disasters (including pandemics such as COVID-19) and pension plan costs. Additional information regarding the factors that may
cause actual results to differ materially from these forward-looking statements is available in our SEC filings, including our 2021 Annual Report on Form 10-K and Quarterly Report on Form 10-Q for
the first quarter of 2022. These forward-looking statements speak only as of the date of this release and except to the extent required by applicable law, the Company does not assume any obligation
to update or revise any forward-looking statement, whether as a result of new information, future events and developments or otherwise.
With respect to the non-GAAP financial measures referenced in the following presentation, definitions and the accompanying information required by SEC Regulation G can be found in this
presentation or in the “Investors” section of Danaher’s web site, www.danaher.com, under the heading “Financial Reports” and subheading “Quarterly Earnings.” In addition, in addressing various
financial metrics the presentation describes certain of the more significant factors that impacted year-over-year performance. For additional factors that impacted year-over-year performance, please
refer to our earnings release and the other related presentation materials supplementing today’s call, all of which are available in the “Investors” section of Danaher’s web site under the heading
“Financial Reports” and subheading “Quarterly Earnings,” as well as our first quarter 2022 Quarterly Report on Form 10-Q. All references in this presentation (1) to financial metrics relate only to the
continuing operations of Danaher’s business, unless otherwise noted; and (2) to “growth” or other period-to-period changes refer to year-over-year comparisons unless otherwise indicated. We may
also describe certain products and devices which have applications submitted and pending for certain regulatory approvals.

-- 2 of 25 --

First Quarter 2022 Performance Summary
$6,858 $7,688
Q1 2021 	Q1 2022
$2.52
$2.76
Q1 2021 	Q1 2022
Throughout this presentation, with respect to revenue performance, for the definitions of “Acquisitions,” "Divestitures," “Core,” and “FX,” please refer to the accompanying information required by Regulation G, located at the end of this presentation and on the "Investors"
section of Danaher's website.
($ millions)
ADJUSTED DILUTED NET
EARNINGS PER COMMON SHARE
+9.5%
REVENUE
+12.0%
Core +12.0%
Acquisitions +2.0%
FX -2.0%

-- 3 of 25 --

First Quarter 2022 Performance Summary
29.1% 	28.3%
Q1 2021 	Q1 2022
-80 BPS
Core -65 bps
Acquisitions -40 bps
Other +25 bps
Throughout this presentation when referred to in connection with operating profit margins, “Acquisitions” refers to the impact of businesses owned for less than one year or disposed of during such period and not treated as discontinued operations, "Other" refers to the impact of certain first
quarter 2021 acquisition-related fair value adjustments associated with the acquisition of Cytiva and impairment and other charges incurred in 2021 and 2022, and “Core” refers to all other year-over-year operating profit margin changes; for further description of these items, please refer to the
accompanying information required by Regulation G, located at the end of this presentation and on the "Investors" section of Danaher's website. For the definition of Free Cash Flow, please refer to the accompanying information required by Regulation G, located at the end of this presentation
and on the "Investors" section of Danaher's website.
$1,632
$1,720
Q1 2021 	Q1 2022
+5.5%
($ millions)
OPERATING PROFIT
MARGIN
FREE CASH FLOW
PERFORMANCE

-- 4 of 25 --

First Quarter 2022: Life Sciences
32.5% 28.8%
Q1 2021 	Q1 2022
$3,546
$3,882
Q1 2021 	Q1 2022
5
-370 BPS
Core -250 bps
Acquisitions -150 bps
Other +30 bps
($ millions)
OPERATING PROFIT MARGIN	REVENUE
+9.5%
Core +7.5%
Acquisitions +4.0%
FX -2.0%

-- 5 of 25 --

First Quarter 2022: Diagnostics
28.7% 33.5%
Q1 2021 	Q1 2022
$2,178
$2,644
Q1 2021 	Q1 2022
6
+21.5%
Core +22.5%
Acquisitions +1.0%
FX -2.0%
+480 BPS
Core +400 bps
Acquisitions +45 bps
Other +35 bps
($ millions)
OPERATING PROFIT MARGIN	REVENUE

-- 6 of 25 --

First Quarter 2022: Environmental &
Applied Solutions
25.1% 20.3%
Q1 2021 	Q1 2022
$1,134 $1,162
Q1 2021 	Q1 2022
7
+2.5%
Core +6.5%
Divestitures -2.5%
FX -1.5%
-480 bps
Core -520 bps
Divestitures +50 bps
Other -10 bps
($ millions)
OPERATING PROFIT MARGIN	REVENUE

-- 7 of 25 --

8
GUIDANCE

-- 8 of 25 --

Q & A
9

-- 9 of 25 --



-- 10 of 25 --

DANAHER CORPORATION
RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES
THREE-MONTH PERIODS ENDED APRIL 1, 2022 AND APRIL 2, 2021

-- 11 of 25 --

TABLE OF CONTENTS
Page
1 Core Sales Growth by Segment and Base Business Core Sales Growth
1 Forecasted Core Sales Growth and Base Business Core Sales Growth
2 Segment Sales, Operating Profit and Adjusted Operating Profit
3 Adjusted EBITDA and Adjusted EBITDA Margin
5 Other Non-GAAP Adjusted P&L Measures
8 Adjusted Average Common Stock and Common Equivalent Diluted Shares Outstanding
9 Year-Over-Year Core Operating Margin Changes
10 Free Cash Flow and Free Cash Flow to Net Earnings Conversion Ratio
11 Statement Regarding Non-GAAP Measures
FORWARD-LOOKING STATEMENTS DISCLOSURE
Statements in this document that are not strictly historical, including any statements regarding events or developments that we believe or anticipate will or may occur in the future are "forward-looking" statements
within the meaning of the federal securities laws. There are a number of important factors that could cause actual results, developments and business decisions to differ materially from those suggested or indicated
by such forward-looking statements and you should not place undue reliance on any such forward-looking statements. These factors include, among other things, the highly uncertain and unpredictable severity,
magnitude and duration of the COVID-19 pandemic (and the related governmental, business and community responses thereto) on our business, results of operations and financial condition, the impact of our debt
obligations on our operations and liquidity, deterioration of or instability in the economy, the markets we serve and the financial markets (including as a result of the COVID-19 pandemic), uncertainties relating to
U.S. laws or policies, including potential changes in U.S. trade policies and tariffs and the reaction of other countries thereto, contractions or growth rates and cyclicality of markets we serve, competition, our
ability to develop and successfully market new products and technologies and expand into new markets, the potential for improper conduct by our employees, agents or business partners, our compliance with
applicable laws and regulations (including rules relating to off-label marketing and other regulations relating to medical devices and the health care industry), the results of our clinical trials and perceptions thereof,
our ability to effectively address cost reductions and other changes in the health care industry, our ability to successfully identify and consummate appropriate acquisitions and strategic investments and successfully
complete divestitures and other dispositions, our ability to integrate the businesses we acquire and achieve the anticipated growth, synergies and other benefits of such acquisitions, contingent liabilities and other
risks relating to acquisitions, investments, strategic relationships and divestitures (including tax-related and other contingent liabilities relating to past and future IPOs, split-offs or spin-offs), security breaches or
other disruptions of our information technology systems or violations of data privacy laws, the impact of our restructuring activities on our ability to grow, risks relating to potential impairment of goodwill and
other intangible assets, currency exchange rates, tax audits and changes in our tax rate and income tax liabilities, changes in tax laws applicable to multinational companies, litigation and other contingent liabilities
including intellectual property and environmental, health and safety matters, the rights of the United States government to use, disclose and license certain intellectual property we license if we fail to
commercialize it, risks relating to product, service or software defects, product liability and recalls, risks relating to product manufacturing, our relationships with and the performance of our channel partners,
uncertainties relating to collaboration arrangements with third-parties, commodity costs and surcharges, our ability to adjust purchases and manufacturing capacity to reflect market conditions, reliance on sole
sources of supply, the impact of deregulation on demand for our products and services, the impact of climate change, or legal or regulatory measures to address climate change, labor matters and our ability to
recruit, retain and motivate talented employees, international economic, political, legal, compliance, social and business factors (including the impact of the United Kingdom's separation from the European Union
and the impact of the military conflict between Russia and Ukraine), disruptions relating to man-made and natural disasters (including pandemics such as COVID-19) and pension plan costs. Additional information
regarding the factors that may cause actual results to differ materially from these forward-looking statements is available in our SEC filings, including our 2021 Annual Report on Form 10-K and Quarterly Report
on Form 10-Q for the first quarter of 2022. These forward-looking statements speak only as of the date of this document and except to the extent required by applicable law, the Company does not assume any
obligation to update or revise any forward-looking statement, whether as a result of new information, future events and developments or otherwise.

-- 12 of 25 --

% Change Three-Month Period Ended April 1, 2022 vs. Comparable 2021
Period
Segments
Total Company Life Sciences Diagnostics Environmental &
Applied Solutions
Total sales growth (GAAP) 12.0 % 9.5 % 21.5 % 2.5 %
Impact of:
Acquisitions/divestitures (2.0) (4.0) (1.0) 2.5
Currency exchange rates 2.0 2.0 2.0 1.5
Core sales growth (non-GAAP) 12.0 % 7.5 % 22.5 % 6.5 %
Impact of COVID-19 related testing (4.0)
Base business core sales growth (non-GAAP) 8.0 %
Note: While we expect overall demand for the Company’s COVID-19 related products to moderate as and to the extent the pandemic subsides, as the pandemic evolves toward endemic
status we believe a level of demand for the Company’s products that support COVID-19 related vaccines and therapeutics (including initiatives that seek to prevent or mitigate similar, future
pandemics) and COVID-19 testing will continue. However, on a relative basis, we expect the level of ongoing demand for products supporting COVID-19 testing will be subject to more
fluctuations in demand than the level of demand for products supporting COVID-19 related vaccines and therapeutics. Therefore, beginning with the first quarter of 2022, in addition to
disclosing core revenue growth, we disclose “base business core sales growth” on a basis that excludes revenues related to COVID-19 testing and includes revenues from products that
support COVID-19 related vaccines and therapeutics. We believe this additional measure provides useful information to investors by facilitating period-to-period comparisons of our
financial performance and identifying underlying growth trends in the Company’s business that otherwise may be obscured by fluctuations in demand for COVID-19 testing as a result of the
pandemic.
Forecasted Core Sales Growth and Base Business Core Sales Growth 1
% Change Three-Month
Period Ending July 1,
2022 vs. Comparable
2021 Period
% Change Year Ending
December 31, 2022 vs.
Comparable 2021
Period
Core sales growth (non-GAAP) +Low-single digit +Mid-single digit
Impact of COVID-19 related testing +Low-single digit +Low-single digit
Base business core sales growth (non-GAAP) +Mid-single digit +High-single digit
1 We do not reconcile these measures to the comparable GAAP measure because of the inherent difficulty in predicting and estimating the future impact and timing of currency translation,
acquisitions and divested product lines, which would be reflected in any forecasted GAAP revenue.
DANAHER CORPORATION
Core Sales Growth by Segment and Base Business Core Sales Growth
1

-- 13 of 25 --

Sales (GAAP)
Life Sciences $ 3,882 $ 3,546
Diagnostics 2,644 2,178
Environmental & Applied Solutions 1,162 1,134
Total Company $ 7,688 $ 6,858
Operating Profit (GAAP)
Life Sciences $ 1,118 $ 1,151
Diagnostics 886 626
Environmental & Applied Solutions 236 285
Other (68) (65)
Total Company $ 2,172 $ 1,997
Amortization of Intangible Assets (GAAP)
Life Sciences $ 321 $ 277
Diagnostics 51 51
Environmental & Applied Solutions 14 16
Total Company $ 386 $ 344
Other Operating Profit Adjustments 2
Life Sciences $ 38 $ 46
Diagnostics 3 10
Environmental & Applied Solutions 1 —
Other 1 —
Total Company $ 43 $ 56
Adjusted Operating Profit (non-GAAP) 3
Life Sciences $ 1,477 $ 1,474
Diagnostics 940 687
Environmental & Applied Solutions 251 301
Other (67) (65)
Total Company $ 2,601 $ 2,397
Three-Month Period Ended
April 1, 2022 April 2, 2021
2 Refer to the Reconciliation of GAAP to Adjusted P&L Measures for a description of the components of Other Operating Profit Adjustments.
3 Adjusted Operating Profit (non-GAAP) is defined as operating profit (GAAP) plus amortization of intangible assets (GAAP) plus (minus) Other Operating Profit Adjustments (as defined).
DANAHER CORPORATION
Segment Sales, Operating Profit and Adjusted Operating Profit
($ in millions)
2

-- 14 of 25 --

Three-Month Period Ended April 1, 2022
Life Sciences Diagnostics
Environmental
& Applied
Solutions Other Total Company
Net Earnings (GAAP) $ 1,725
Interest, Net 53
Other Nonoperating (Income) Expense 20
Income Taxes 374
Operating Profit (GAAP) $ 1,118 $ 886 $ 236 $ (68) $ 2,172
Other Operating Profit Adjustments 2 38 3 1 1 43
Depreciation 72 94 11 2 179
Amortization of Intangible Assets 321 51 14 — 386
Adjusted EBITDA (Non-GAAP) $ 1,549 $ 1,034 $ 262 $ (65) $ 2,780
Interest, Net (53)
Other Nonoperating Income (Expense) (20)
Income Taxes (374)
Other Operating Profit Adjustments 2 (43)
Depreciation (179)
Amortization of Intangible Assets (386)
Net Earnings (GAAP) $ 1,725
Sales (GAAP) $ 3,882 $ 2,644 $ 1,162 $ 7,688
Net Earnings Margin (GAAP) 22.4 %
Adjusted EBITDA Margin (Non-GAAP) 4 39.9 % 39.1 % 22.5 % 36.2 %
2 Refer to the Reconciliation of GAAP to Adjusted P&L Measures for a description of the components of Other Operating Profit Adjustments.
4 Adjusted EBITDA Margin (Non-GAAP) is defined as Adjusted EBITDA (Non-GAAP) divided by sales.
DANAHER CORPORATION
Adjusted EBITDA and Adjusted EBITDA Margin
($ in millions)
3

-- 15 of 25 --

Three-Month Period Ended April 2, 2021
Life Sciences Diagnostics
Environmental
& Applied
Solutions Other Total Company
Net Earnings (GAAP) $ 1,702
Interest, Net 54
Other Nonoperating (Income) Expense (140)
Income Taxes 381
Operating Profit (GAAP) $ 1,151 $ 626 $ 285 $ (65) $ 1,997
Other Operating Profit Adjustments 2 46 10 — — 56
Depreciation 52 93 11 2 158
Amortization of Intangible Assets 277 51 16 — 344
Adjusted EBITDA (Non-GAAP) $ 1,526 $ 780 $ 312 $ (63) $ 2,555
Interest, Net (54)
Other Nonoperating Income (Expense) 140
Income Taxes (381)
Other Operating Profit Adjustments 2 (56)
Depreciation (158)
Amortization of Intangible Assets (344)
Net Earnings (GAAP) $ 1,702
Sales (GAAP) $ 3,546 $ 2,178 $ 1,134 $ 6,858
Net Earnings Margin (GAAP) 24.8 %
Adjusted EBITDA Margin (Non-GAAP) 4 43.0 % 35.8 % 27.5 % 37.3 %
2 Refer to the Reconciliation of GAAP to Adjusted P&L Measures for a description of the components of Other Operating Profit Adjustments.
4 Adjusted EBITDA Margin (Non-GAAP) is defined as Adjusted EBITDA (Non-GAAP) divided by sales.
DANAHER CORPORATION
Adjusted EBITDA and Adjusted EBITDA Margin
($ in millions)
4

-- 16 of 25 --

Three-Month Period Ended April 1, 2022
Sales Cost of sales Gross profit
margin Operating
profit Operating
profit margin
Earnings
before
income taxes Income taxes
Net earnings for
calculation of
diluted earnings
per common share
Diluted net
earnings per
common
share 5
Reported (GAAP) $ 7,688 $ (2,983) 61.2 % $ 2,172 28.3 % $ 2,099 $ (374) $ 1,704 J $ 2.31
Amortization of acquisition-related
intangible assets A — — — 386 5.0 386 386 0.52
Fair value net (gains) losses on
investments B — — — — — 24 24 0.03
Impairments and other charges C — 18 0.2 43 0.6 43 43 0.06
Loss on partial settlement of a defined
benefit plan D — — — — — 10 10 0.01
Tax effect of the above adjustments G (85) (85) (0.11)
Discrete tax adjustments H (41) (41) (0.06)
MCPS "as if converted" I — — — — — — — 21 —
Rounding — — — — (0.1) — — — —
Adjusted (Non-GAAP) $ 7,688 $ (2,965) 61.4 % $ 2,601 33.8 % $ 2,562 $ (500) $ 2,062 $ 2.76
Three-Month Period Ended April 1, 2022
Sales
Selling,
general and
administrative
expenses
Selling,
general and
administrative
expenses as a
% of sales
Research and
development
expenses
Research and
development
expenses as a
% of sales
Nonoperating
income
(expense), net
(excluding
interest)
Interest
income
(expense), net
Reported (GAAP) $ 7,688 $ (2,092) (27.2) % $ (441) (5.7) % $ (20) $ (53)
Amortization of acquisition-related
intangible assets A — 386 5.0 — — — —
Fair value net (gains) losses on
investments B — — — — — 24 —
Impairments and other charges C — 25 0.3 — — — —
Loss on partial settlement of a defined
benefit plan D — — — — — 10 —
Adjusted (Non-GAAP) $ 7,688 $ (1,681) (21.9) % $ (441) (5.7) % $ 14 $ (53)
5 Each of the per share amounts above have been calculated assuming the Mandatory Convertible Preferred Stock (“MCPS”) had been converted into shares of common stock.
DANAHER CORPORATION
Other Non-GAAP Adjusted P&L Measures
($ in millions, except per share data)
5

-- 17 of 25 --

Three-Month Period Ended April 2, 2021
Sales Cost of sales Gross profit
margin Operating
profit Operating
profit margin
Earnings
before
income taxes Income taxes
Net earnings for
calculation of
diluted earnings
per common share
Diluted net
earnings per
common
share 5
Reported (GAAP) $ 6,858 $ (2,605) 62.0 % $ 1,997 29.1 % $ 2,083 $ (381) $ 1,681 J $ 2.29
Amortization of acquisition-related
intangible assets A — — — 344 5.0 344 344 0.46
Fair value net (gains) losses on
investments B — — — — — (116) (116) (0.15)
Impairments and other charges C — — — 10 0.1 10 10 0.01
Acquisition-related items E 17 29 0.7 46 0.7 46 46 0.06
Gain on disposition of certain product
lines F — — — — — (13) (13) (0.02)
Tax effect of the above adjustments G (57) (57) (0.08)
Discrete tax adjustments H (44) (44) (0.06)
MCPS "as if converted" I — — — — — — — 21 —
Rounding — — (0.2) — — — — — 0.01
Adjusted (Non-GAAP) $ 6,875 $ (2,576) 62.5 % $ 2,397 34.9 % $ 2,354 $ (482) $ 1,872 $ 2.52
Three-Month Period Ended April 2, 2021
Sales
Selling,
general and
administrative
expenses
Selling,
general and
administrative
expenses as a
% of sales
Research and
development
expenses
Research and
development
expenses as a
% of sales
Nonoperating
income
(expense), net
(excluding
interest)
Interest
income
(expense), net
Reported (GAAP) $ 6,858 $ (1,876) (27.4) % $ (380) (5.5) % $ 140 $ (54)
Amortization of acquisition-related
intangible assets A — 344 5.0 — — — —
Fair value net (gains) losses on
investments B — — — — — (116) —
Impairments and other charges C — 10 0.1 — — — —
Acquisition-related items E 17 — — — — — —
Gain on disposition of certain product
lines F — — — — — (13) —
Rounding — — 0.2 — — — —
Adjusted (Non-GAAP) $ 6,875 $ (1,522) (22.1) % $ (380) (5.5) % $ 11 $ (54)
5 Each of the per share amounts above have been calculated assuming the Mandatory Convertible Preferred Stock (“MCPS”) had been converted into shares of common stock.
DANAHER CORPORATION
Other Non-GAAP Adjusted P&L Measures
($ in millions, except per share data)
6

-- 18 of 25 --

A Amortization of acquisition-related intangible assets in the following historical periods ($ in millions) (only the pretax amounts set forth below are reflected in
the amortization line item above):
Three-Month Period Ended
April 1, 2022 April 2, 2021
Pretax $ 386 $ 344
After-tax 311 274
B Net (gains) losses on the Company's equity and limited partnership investments recorded in the following historical periods ($ in millions) (only the pretax
amounts set forth below are reflected in the fair value net (gains) losses on investments line above):
Three-Month Period Ended
April 1, 2022 April 2, 2021
Pretax (gain) loss $ 24 $ (116)
After-tax (gain) loss 18 (94)
C Charges incurred primarily related to impairments of accounts receivable and inventory as well as accruals for contractual obligations in Russia incurred in the
three-month period ended April 1, 2022 ($43 million pretax as reported in this line item, $40 million after-tax). Impairment charges related to a trade name in the
Diagnostics segment recorded in the three-month period ended April 2, 2021 ($10 million pretax as reported in this line item, $8 million after-tax).
D Loss on a partial settlement of a defined benefit plan as a result of the transfer of a portion of the Company’s non-U.S. pension liabilities related to one defined
benefit plan to a third party in the three-month period ended April 1, 2022 ($10 million pretax as reported in this line item, $9 million after-tax)..
E Costs incurred for fair value adjustments to inventory and deferred revenue related to the acquisition of Cytiva in the three-month period ended April 2, 2021
($46 million pretax as reported in this line item, $36 million after-tax).
F Gain on disposition of certain product lines in the three-month period ended April 2, 2021 ($13 million pretax as reported in this line item, $10 million after-tax).
G This line item reflects the aggregate tax effect of all nontax adjustments reflected in the preceding line items of the table. In addition, the footnotes above
indicate the after-tax amount of each individual adjustment item. Danaher estimates the tax effect of each adjustment item by applying Danaher’s overall
estimated effective tax rate to the pretax amount, unless the nature of the item and/or the tax jurisdiction in which the item has been recorded requires application
of a specific tax rate or tax treatment, in which case the tax effect of such item is estimated by applying such specific tax rate or tax treatment. The MCPS
dividends are not tax deductible and therefore the tax effect of the adjustments does not include any tax impact of the MCPS dividends.
H Discrete tax adjustments and other tax-related adjustments for the three-month period ended April 1, 2022, include the impact of net discrete tax benefits of $41
million related primarily to excess tax benefits from stock-based compensation and the changes in estimates associated with prior period uncertain tax positions.
Discrete tax adjustments and other tax-related adjustments for the three-month period ended April 2, 2021, include the impact of net discrete tax benefits of $44
million related primarily to excess tax benefits from stock-based compensation and the benefit from release of reserves for uncertain tax positions from audit
settlements, net of changes in estimates associated with prior period uncertain tax positions.
I In March 2019, the Company issued $1.65 billion in aggregate liquidation preference of 4.75% MCPS Series A. In May 2020, the Company issued $1.72 billion
in aggregate liquidation preference of 5.0% MCPS Series B. Dividends on the MCPS Series A and Series B are payable on a cumulative basis at an annual rate
of 4.75% and 5.0%, respectively, on the liquidation preference of $1,000 per share. Each share of MCPS Series A converted on April 15, 2022 into 6.6632
shares of Danaher’s common stock. Unless earlier converted, each share of MCPS Series B will automatically convert on April 15, 2023 into between 5.0115
and 6.1391 shares of Danaher’s common stock, subject to further anti-dilution adjustments. The number of shares of Danaher’s common stock issuable on
conversion of the MCPS is determined based on the volume weighted average price (“VWAP”) per share of the Company's common stock over the 20
consecutive trading day period beginning on, and including, the 21st scheduled trading day immediately before April 15, 2022 and April 15, 2023 for the MCPS
Series A and Series B, respectively. For the calculation of net earnings per common share, the impact of the dilutive MCPS is calculated under the if-converted
DANAHER CORPORATION
Other Non-GAAP Adjusted P&L Measures
($ in millions, except per share data)
7

-- 19 of 25 --

method and the related MCPS dividends are excluded. For the purposes of calculating adjusted earnings per common share, the Company has excluded the paid
and anticipated MCPS cash dividends and assumed the “if-converted” method of share dilution (the incremental shares of common stock deemed outstanding
applying the “if-converted” method of calculating share dilution only with respect to any MCPS the conversion of which would be dilutive in the particular
period are referred to as the “Converted Shares”) for any MCPS that were anti-dilutive for the given period. For additional information about the impact of the
MCPS on the calculation of diluted EPS, see note 6 in the Adjusted Average Common Stock and Common Equivalent Diluted Shares Outstanding table below.
J Net earnings for calculation of diluted earnings per common share is summarized as follows ($ in millions):
Three-Month Period Ended
April 1, 2022 April 2, 2021
Net earnings $ 1,725 $ 1,702
MCPS dividends (41) (41)
Net earnings attributable to common stockholders for Basic EPS 1,684 1,661
Adjustment for MCPS dividends for dilutive MCPS 20 20
Net earnings attributable to common stockholders after assumed conversions for Diluted EPS $ 1,704 $ 1,681
Adjusted Average Common Stock and Common Equivalent Diluted Shares Outstanding
(shares in millions)
Three-Month Period Ended
April 1, 2022 April 2, 2021
Average common stock and common equivalent shares outstanding - diluted (GAAP) 6 737.7 735.1
Converted shares 7 8.6 8.6
Adjusted average common stock and common equivalent shares outstanding - diluted (non-GAAP) 746.3 743.7
6 The impact of the MCPS Series A calculated under the if-converted method was dilutive for the three-month periods ended April 1, 2022 and April 2, 2021, and as such 11.0 million shares
underlying the MCPS Series A were included in the calculation of diluted EPS for both three-month periods and the related MCPS Series A dividends of $20 million were excluded from
the calculation of net earnings for diluted EPS for both periods.
The impact of the MCPS Series B calculated under the if-converted method was anti-dilutive for the three-month periods ended April 1, 2022 and April 2, 2021, and as such 8.6 million
shares underlying the MCPS Series B were excluded from the calculation of diluted EPS in both periods and the related MCPS Series B dividends of $21 million were included in the
calculation of net earnings for diluted EPS for both periods.
7 The number of converted shares assumes the conversion of all MCPS and issuance of the underlying shares applying the “if-converted” method of accounting and using an average 20
trading-day trailing VWAP of $281.28 and $218.80 as of April 1, 2022 and April 2, 2021, respectively.
DANAHER CORPORATION
Other Non-GAAP Adjusted P&L Measures
($ in millions, except per share data)
8

-- 20 of 25 --

Segments
Total Company Life Sciences Diagnostics
Environmental
& Applied
Solutions
Three-Month Period Ended April 2, 2021 Operating Profit Margins (GAAP) 29.10 % 32.50 % 28.70 % 25.10 %
First quarter 2022 impact from operating profit margins of businesses that have been owned for
less than one year or were disposed of during such period and did not qualify as discontinued
operations (0.40) (1.50) 0.45 0.50
First quarter 2021 acquisition-related fair value adjustments to inventory and deferred revenue, in
each case related to the acquisition of Cytiva 0.65 1.30 — —
First quarter 2022 impairments of accounts receivable and inventory as well as accruals for
contractual obligations in Russia (0.55) (1.00) (0.10) (0.10)
First quarter 2021 impairment charge related to a trade name in the Diagnostics segment 0.15 — 0.45 —
Year-over-year core operating profit margin changes for the first quarter 2022 (defined as all
year-over-year operating profit margin changes other than the changes identified in the line
items above) (non-GAAP) (0.65) (2.50) 4.00 (5.20)
Three-Month Period Ended April 1, 2022 Operating Profit Margins (GAAP) 28.30 % 28.80 % 33.50 % 20.30 %
Note: The Company deems acquisition-related transaction costs incurred in a given period to be significant (generally relating to the Company’s larger acquisitions) if it
determines that such costs exceed the range of acquisition-related transaction costs typical for Danaher in a given period.
DANAHER CORPORATION
Year-Over-Year Core Operating Margin Changes
9

-- 21 of 25 --

Three-Month Period Ended Year-over-Year
Change	April 1, 2022 April 2, 2021
Total Cash Flows:
Total cash provided by operating activities (GAAP) $ 1,968 $ 1,871
Total cash used in investing activities (GAAP) $ (503) $ (993)
Total cash used in financing activities (GAAP) $ (274) $ (449)
Free Cash Flow:
Total cash provided by operating activities (GAAP) $ 1,968 $ 1,871 ~ 5.0%
Less: payments for additions to property, plant & equipment (capital expenditures) (GAAP) (250) (251)
Plus: proceeds from sales of property, plant & equipment (capital disposals) (GAAP) 2 12
Free cash flow (non-GAAP) $ 1,720 $ 1,632 ~ 5.5%
Free Cash Flow to Net Earnings Conversion Ratio:
Free cash flow from above (non-GAAP) $ 1,720 $ 1,632
Net earnings (GAAP) 1,725 1,702
Free cash flow to net earnings conversion ratio (non-GAAP) 1.00 0.96
We define free cash flow as operating cash flows, less payments for additions to property, plant and equipment (“capital expenditures”) plus the proceeds from sales of plant, property and
equipment (“capital disposals”).
DANAHER CORPORATION
Free Cash Flow and Free Cash Flow to Net Earnings Conversion Ratio
($ in millions)
10

-- 22 of 25 --

Each of the non-GAAP measures set forth above should be considered in addition to, and not as a replacement for or superior to, the comparable GAAP measure, and may
not be comparable to similarly titled measures reported by other companies. Management believes that these measures provide useful information to investors by offering
additional ways of viewing Danaher Corporation’s (“Danaher” or the “Company”) results that, when reconciled to the corresponding GAAP measure, help our investors
to:
• with respect to the profitability-related non-GAAP measures, understand the long-term profitability trends of our business and compare our profitability to prior
and future periods and to our peers;
• with respect to core sales and related sales measures, identify underlying growth trends in our business and compare our sales performance with prior and future
periods and to our peers; and
• with respect to free cash flow and related cash flow measures (the “FCF Measure”), understand Danaher’s ability to generate cash without external financings,
strengthen its balance sheet, invest in its business and grow its business through acquisitions and other strategic opportunities (although a limitation of free cash
flow is that it does not take into account the Company’s debt service requirements and other non-discretionary expenditures, and as a result the entire free cash
flow amount is not necessarily available for discretionary expenditures).
While we expect overall demand for the Company’s COVID-19 related products to moderate as and to the extent the pandemic subsides, as the pandemic evolves toward
endemic status we believe a level of demand for the Company’s products that support COVID-19 related vaccines and therapeutics (including initiatives that seek to
prevent or mitigate similar, future pandemics) and COVID-19 testing will continue. However, on a relative basis, we expect the level of ongoing demand for products
supporting COVID-19 testing will be subject to more fluctuations in demand than the level of demand for products supporting COVID-19 related vaccines and
therapeutics. Therefore, beginning with the first quarter of 2022, in addition to disclosing core revenue growth, we disclose “base business core sales growth” on a basis
that excludes revenues related to COVID-19 testing and includes revenues from products that support COVID-19 related vaccines and therapeutics. We believe this
additional measure provides useful information to investors by facilitating period-to-period comparisons of our financial performance and identifying underlying growth
trends in the Company’s business that otherwise may be obscured by fluctuations in demand for COVID-19 testing as a result of the pandemic.
Management uses these non-GAAP measures to measure the Company’s operating and financial performance, and uses core sales and non-GAAP measures similar to
Adjusted Diluted Net Earnings Per Common Share and the FCF Measure in the Company’s executive compensation program.
• The items excluded from the non-GAAP measures set forth above have been excluded for the following reasons:
◦ Amortization of Intangible Assets. We exclude the amortization of acquisition-related intangible assets because the amount and timing of such charges
are significantly impacted by the timing, size, number and nature of the acquisitions we consummate. While we have a history of significant acquisition
activity we do not acquire businesses on a predictable cycle, and the amount of an acquisition’s purchase price allocated to intangible assets and related
amortization term are unique to each acquisition and can vary significantly from acquisition to acquisition. Exclusion of this amortization expense
facilitates more consistent comparisons of operating results over time between our newly acquired and long-held businesses, and with both acquisitive
and non-acquisitive peer companies. We believe however that it is important for investors to understand that such intangible assets contribute to sales
generation and that intangible asset amortization related to past acquisitions will recur in future periods until such intangible assets have been fully
amortized.
◦ Restructuring Charges. We exclude costs incurred pursuant to discrete restructuring plans that are fundamentally different (in terms of the size, strategic
nature and planning requirements, as well as the inconsistent frequency, of such plans) from the ongoing productivity improvements that result from
application of the Danaher Business System. Because these restructuring plans are incremental to the core activities that arise in the ordinary course of
our business and we believe are not indicative of Danaher’s ongoing operating costs in a given period, we exclude these costs to facilitate a more
consistent comparison of operating results over time.
DANAHER CORPORATION
Statement Regarding Non-GAAP Measures
11

-- 23 of 25 --

◦ Other Adjustments. With respect to the other items excluded from Adjusted Diluted Net Earnings Per Common Share, we exclude these items because
they are of a nature and/or size that occur with inconsistent frequency, occur for reasons that may be unrelated to Danaher's commercial performance
during the period and/or we believe that such items may obscure underlying business trends and make comparisons of long-term performance difficult.
For example, we excluded the first quarter 2022 charge for asset impairments, accruals for contractual obligations and similar items related to our Russia
operations because, even though it is possible we could incur additional charges in the future, we do not believe these charges are indicative of
Danaher’s ongoing operating costs.
• With respect to adjusted average common stock and common equivalent shares outstanding, Danaher’s Mandatory Convertible Preferred Stock (“MCPS”) Series
A converted into Danaher common stock on April 15, 2022 and MCPS Series B will mandatorily convert into Danaher common stock on the mandatory
conversion date, which is expected to be April 15, 2023 (unless converted or redeemed earlier in accordance with the terms of the applicable certificate of
designations). With respect to the calculation of Adjusted Diluted Net Earnings Per Common Share, we apply the “if converted” method of share dilution to the
MCPS Series A and B in all applicable periods irrespective of whether such preferred shares would be dilutive or anti-dilutive in the period. We believe this
presentation provides useful information to investors by helping them understand what the net impact will be on Danaher’s earnings per share-related measures
once the MCPS convert into Danaher common stock.
• With respect to core operating profit margin changes, in addition to the explanation set forth in the bullets above relating to the “other adjustments”, we exclude
the impact of businesses owned for less than one year (or disposed of during such period and not treated as discontinued operations) because the timing, size,
number and nature of such transactions can vary significantly from period to period and may obscure underlying business trends and make comparisons of long-
term performance difficult.
• We calculate adjusted EBITDA by adding to operating profit amounts equal to depreciation and amortization and making the other adjustments reflected in the
applicable tables above, which allows us to calculate and disclose such measure by segment. Given Danaher’s diversification, we believe this helps our investors
compare the profitability of our individual segments to peer companies with like business lines.
• With respect to core sales related measures, (1) we exclude the impact of currency translation because it is not under management’s control, is subject to
volatility and can obscure underlying business trends, and (2) we exclude the effect of acquisitions and divested product lines because the timing, size, number
and nature of such transactions can vary significantly from period-to-period and between us and our peers, which we believe may obscure underlying business
trends and make comparisons of long-term performance difficult.
• With respect to the FCF Measure, we exclude payments for additions to property, plant and equipment (net of the proceeds from capital disposals) to demonstrate
the amount of operating cash flow for the period that remains after accounting for the Company’s capital expenditure requirements.
With respect to forecasted core sales related measures, we do not reconcile these measures to the comparable GAAP measure because of the inherent difficulty in
predicting and estimating the future impact and timing of currency translation, acquisitions and divested product lines, which would be reflected in any forecasted GAAP
revenue.
DANAHER CORPORATION
Statement Regarding Non-GAAP Measures
12

-- 24 of 25 --

13

-- 25 of 25 --